Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: Phase 2 LUNA Study Update
Glenn C. Yiu, MD, PhD
Updates from the Field
2025
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Updates from the Field
2018
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more